ByTrending Posts
Can Dual Regulatory Approvals Position UltraGreen.ai as a…
Singapore – December 31, 2025 — UltraGreen.ai Limited, a Singapore-based company specializing in fluorescence-guided surgery and digital health…
What Does SoftBank’s $41 Billion Bet on OpenAI…
Global – December 2025 — SoftBank’s $41 billion investment in OpenAI represents one of the most consequential capital…
Did Ophthalmic Therapy Approvals in 2025 Redefine Vision…
Global – December 2025 — The ophthalmology therapeutic area entered a renewed phase of innovation in 2025, driven…
Did Metabolic Therapy Approvals in 2025 Reset the…
Global – December 2025 — The metabolic therapeutic area emerged as one of the most transformative forces in…
Did Renal Therapy Approvals in 2025 Redefine Kidney…
Global – December 2025 — The renal therapeutic area emerged as a renewed focus of innovation in 2025,…
Did Cardiovascular Approvals in 2025 Signal a New…
Global – December 2025 — The cardiovascular (CV) therapeutic area re-emerged as a strategic growth engine in 2025,…
Did Infectious Disease Approvals in 2025 Redefine Global…
Global – December 2025 — The infectious diseases (ID) landscape underwent a structural recalibration in 2025, shaped by…
Did Neuroscience Approvals in 2025 Mark a Turning…
Global – December 2025 — The neuroscience sector experienced a long-anticipated resurgence in 2025, driven by regulatory approvals…
Did Immunology Approvals in 2025 Redefine Autoimmune Care—and…
Global – December 2025 — The immunology sector entered a decisive transformation in 2025, marked by major regulatory…
Trending Posts
Latest Stories
Innovent and Eli Lilly Expand Strategic Alliance to Advance Immunology and Oncology Innovation
Shanghai, China – February, 2026 – Innovent Biologics Inc today announced a new strategic collaboration…
Eli Lilly to Acquire Orna Therapeutics in Deal Valued at Up to $2.4 Billion to Advance In Vivo Cell Therapy Platform
Indianapolis, IN – February 9, 2026 – Eli Lilly and Company today announced it has…
AstraZeneca Reports 2025 Performance with Strong Brand Momentum Across Core Therapeutic Areas
AstraZeneca today announced its full-year 2025 results, reflecting continued growth across oncology, cardiovascular-renal-metabolism (CVRM), respiratory…
GSK Reports Full-Year 2025 Results with Strategic Portfolio Focus
GSK today reported its full-year performance for 2025 and outlined its strategic approach to long-term…
Gallery
